BioStock

Prenumeration

Lipum AB: BioStock: Lipum seeks patent protecting inflammation-driven cancer treatment

2024-04-03 10:49:30

Lipum has submitted an international patent application for SOL-116 as a treatment for inflammation-driven cancer. The patent application is based on the company's research demonstrating that SOL-116 inhibits the growth of cancer cells by blocking the target protein BSSL. Additionally, studies on breast cancer patients indicate that high expression of BSSL correlates with a poor prognosis and shorter survival.

Read the full article at biostock.se (https://www.biostock.se/en/):

https://www.biostock.se/en/2024/04/lipum-seeks-patent-protecting-inflammation-driven-cancer-treatment/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se

↑	Select newer press release
↓	Select older press release
←	Navigate backwards
→	Navigate forward
Enter	Navigate to line in focus
Tab	Focus next link
A or 1	Open First attachment
S or 2	Open Second attachment
D or 3	Open Third attachment
F or 4	Open Fourth attachment
I	Show company information
PgUp	Select newest press release
PgDown	Select oldest press release
L	Focus on filer bar
N	Increase preview window size
M	Decrease preview window size
Esc	Escape from mode

BioStock

Prenumeration

Ett mail har skickats till den givna adressen. För att logga in, klicka på "Login" i mailet för att verifiera ditt konto

Företag

Pressmeddelanden